Intellia Therapeutics, Inc. (NASDAQ:NTLA) went up by 1.12% from its latest closing price when compared to the 1-year high value of $25.56 and move down -18.44%, while NTLA stocks collected 6.83% of gains with the last five trading sessions. Press Release reported on 08/06/20 that Intellia Therapeutics Announces Second Quarter 2020 Financial Results
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Worth an Investment?
Intellia Therapeutics, Inc. (NASDAQ: NTLA) The 36 Months beta value for NTLA stocks is at 1.64, while 5 of the analysts out of 11 who provided ratings for Intellia Therapeutics, Inc. stocks as a “buy” while 2 as overweight, 4 rated it as hold and 0 as sell. The average price we get from analysts is $24.75 which is $8.57 above current price. NTLA currently has a short float of 22.39% and public float of 48.95M with average trading volume of 900.28K shares.
NTLA Market Performance
NTLA stocks went up by 6.83% for the week, with the monthly jump of 21.17% and a quarterly performance of 6.52%, while its annual performance rate touched 52.08%. The simple moving average for the period of the last 20 days is 6.08% for NTLA stocks with the simple moving average of 30.56% for the last 200 days.
Analysts’ Opinion on Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Many brokerage firms have already submitted their reports for NTLA stocks, with Oppenheimer repeating the rating for NTLA shares by setting it to “Outperform”. The predicted price for NTLA socks in the upcoming period according to Oppenheimer is $11 based on the research report published on February 28, 2020.
Wedbush, on the other hand, stated in their research note that they expect to see NTLA stock at the price of $16. The rating they have provided for NTLA stocks is “Neutral” according to the report published on February 14, 2020.
Raymond James gave “ Outperform” rating to NTLA stocks, setting the target price at $16 in the report published on November 1, 2019.
NTLA Stocks 2.96% Far from 50 Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, Intellia Therapeutics, Inc. was unable to take a rebound, for now settling with -15.57% of loss for the given period.
The stock volatility was left at 5.44%, however, within the period of a single month, the volatility rate increased by 5.04%, while the shares surge at the distance of +12.10% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +1.94% upper at the present time.
In the course of the last 5 trading sessions, NTLA went up by +6.83%, which changed the moving average for the period of 200 days to the total of +54.81% of gains for the stock in comparison to the 20-day moving average settled at $20.46. In addition, Intellia Therapeutics, Inc. saw 47.10% in overturn over the period of a single year with a tendency to cut further gains.
NTLA Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Intellia Therapeutics, Inc. (NTLA), starting from Rivera Jose E, who sold 5,615 shares at the price of $21.00 back on Aug 18. After this action, Rushing now owns 31,909 shares of Intellia Therapeutics, Inc., valued at $117,915 with the latest closing price.
LEONARD JOHN M., the President and CEO of Intellia Therapeutics, Inc., sold 5,000 shares at the value of $21.83 during a trade that took place back on Aug 06, which means that LEONARD JOHN M. is holding 467,352 shares at the value of $109,150 based on the most recent closing price.
NTLA Stock Fundamentals
The current profitability levels are settled at -246.78 for the present operating margin. The net margin for Intellia Therapeutics, Inc. stands at -230.92. Total capital return value is set at -37.57, while invested capital returns managed to touch -35.52. Equity return holds the value -40.60%, with -31.20% for asset returns.
Based on Intellia Therapeutics, Inc. (NTLA), the company’s capital structure generated 6.81 points for debt to equity in total, while total debt to capital is set at the value of 6.37.
The value for Enterprise to Sales is 10.02 with debt to enterprise value settled at 0.04. The receivables turnover for Intellia Therapeutics, Inc. is 7.09 with the total asset turnover at the value of 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.12.